REPLIGEN CORP (RGEN) Overview
- 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual 0.09; Beat / miss (m).
- 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual 0.15; Beat / miss (m).
- 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual 0.26; Beat / miss (m).
- 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual 0.26; Beat / miss (m).
Stock Price Chart
View more →Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
- Last close
- $173.54
- Previous close
- $194.57
- Change
- -$21.03
- Change (%)
- -10.81%
- Close date
- 2026-11-06
- Previous close date
- 2026-09-29
- Open
- (m)
- Day high
- (m)
- Day low
- (m)
- Last session volume
- (m)
- Last session value
- (m)
- Currency
- USD
- Price basis
- split-adjusted
- Volume basis
- (m)
Performance
View more →Cumulative total returns · 2026-09-29
YTD
- RGEN
- +18.74%
- S&P 500
- (m)
1 year
- RGEN
- +56.80%
- S&P 500
- (m)
3 years
- RGEN
- +22.36%
- S&P 500
- (m)
5 years
- RGEN
- -32.01%
- S&P 500
- (m)
Earnings trends
View more →Earnings per share
USD / share · As filed
30 Jun 2026 ○ Estimate (m) ● Actual 0.09
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 1 Apr 2026 | 30 Jun 2026 | (m) | 0.09 | (m) | (m) |
| 1 Jan 2026 | 31 Mar 2026 | (m) | 0.15 | (m) | (m) |
| 1 Jul 2025 | 30 Sept 2025 | (m) | 0.26 | (m) | (m) |
| 1 Apr 2025 | 30 Jun 2025 | (m) | 0.26 | (m) | (m) |
| 1 Jan 2025 | 31 Mar 2025 | (m) | 0.10 | (m) | (m) |
31 Dec 2025 ○ Estimate (m) ● Actual 0.86
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 1 Jan 2025 | 31 Dec 2025 | (m) | 0.86 | (m) | (m) |
| 1 Jan 2024 | 31 Dec 2024 | (m) | -0.46 | (m) | (m) |
| 1 Jan 2023 | 31 Dec 2023 | (m) | 0.63 | (m) | (m) |
| 1 Jan 2022 | 31 Dec 2022 | (m) | 3.24 | (m) | (m) |
| 1 Jan 2021 | 31 Dec 2021 | (m) | 2.24 | (m) | (m) |
(m)
Revenue vs. Earnings
USD
31 Mar 2018 ■ Revenue 44.83M ■ Earnings 3.45M — Profit margin 7.69%
31 Dec 2017 ■ Revenue 141.24M ■ Earnings 28.35M — Profit margin 20.07%
Analyst insights
View more →| Ratings | Buy | Hold | Sell | Other ratings | Last Close | Average Target | Upside | High Target | Low Target |
|---|---|---|---|---|---|---|---|---|---|
| (m) | (m) | (m) | (m) | (m) | $173.54 | (m) | (m) | (m) | (m) |
Recent news
View more →(m)
YouTube videos mentioning RGEN
View more →(m)
Statistics
View more →Retained observations as of 2026-11-11; financial period ending 31 Mar 2018.
- Forward P/E
- (m)
- PEG ratio · 5-year expected
- (m)
- Shares held by insiders
- (m)
- Insider transactions · change (%)
- (m)
- Shares held by institutions
- (m)
- Institutional transactions · change (%)
- (m)
- Diluted EPS · 12 month
- (m)
- EPS estimate · next quarter
- (m)
- EPS estimate · next year
- (m)
- EPS growth · current annual estimate
- (m)
- EPS growth · next annual estimate
- (m)
- EPS growth · next 5 years expected
- (m)
- EPS growth · past 3 years annualized
- (m)
- EPS growth · past 5 years annualized
- (m)
- EPS change · 12 months vs prior year
- (m)
- EPS change · latest quarter vs previous quarter
- (m)
- Latest earnings report date
- (m)
- EPS surprise · latest reported quarter
- (m)
- Net income · 12 month
- $28.73M
- Gross margin · 12 months
- 53.22%
- Profit margin
- 18.48%
- Return on assets · 12 month
- 5.56%
- Named executive and board stock awards · latest fiscal year
- (m)
- Index membership
- (m)
- Employees
- 2.00K
- IPO date
- (m)
- Options available
- (m)
- Shortable
- (m)
- Analyst recommendation
- (m)
- Analyst target price
- (m)
- Price volatility · week
- (m)
- Price volatility · month
- (m)
- Average true range · 14 sessions
- (m)
- Relative strength index · 14 sessions
- (m)
- Relative volume
- (m)
- Average daily volume
- 1.08M
- Latest session volume
- (m)
- Last session value
- (m)
- 30 days ago session value
- (m)
- 1 year ago session value
- (m)
- Number of trades
- (m)
- Total return · week
- 4.19%*
- Total return · month
- 10.38%*
- Total return · quarter
- 42.02%*
- Total return · half year
- 76.69%*
- Total return · year to date
- 18.74%*
- Total return · 1 year
- 56.80%*
- Total return · 3 years
- 22.36%*
- Total return · 5 years
- -32.01%*
- Market cap
- (m)
- Book value per share · latest quarter
- (m)
- Price / cash · latest quarter
- (m)
- Enterprise value
- (m)
- Enterprise value / revenue
- (m)
- Enterprise value / EBITDA
- (m)
- Dividend · 12 months per share
- (m)
- Dividend ex-date
- (m)
- Next dividend ex-date
- (m)
- Next dividend amount per share
- (m)
- Dividend growth · 3 years annualized
- (m)
- Dividend growth · 5 years annualized
- (m)
- Revenue · 12 month
- $155.48M
- Revenue growth · past 3 years annualized
- (m)
- Revenue growth · past 5 years annualized
- (m)
- Revenue change · 12 months vs prior year
- (m)
- Revenue change · latest quarter vs previous quarter
- (m)
- Revenue surprise · latest reported quarter
- (m)
- Levered free cash flow · 12 month
- (m)
- Debt / equity · latest quarter
- (m)
- Long-term debt / equity · latest quarter
- (m)
- Return on equity · 12 month
- (m)
- Return on invested capital · 12 months
- (m)
- Previous close
- (m)
- Latest closing price
- (m)
- Latest session change (%)
- (m)
- 52-week high
- (m)
- 52-week low
- (m)
- Price vs 20-session moving average
- (m)
- Price vs 50-session moving average
- (m)
- Price vs 200-session moving average
- (m)
- Float shares
- (m)
- Short float (%)
- (m)
- Short ratio (days to cover)
- (m)
- Short interest (shares)
- (m)
Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.
Holders breakdown
View more →| Breakdown | Ownership |
|---|---|
| (m) | Shares held by all insiders |
| (m) | Shares held by institutions |
| (m) | Float held by institutions |
| (m) | Institutions holding shares |
Other holders
(m)
Insider holders
(m)
Top institutional holders
(m)
Top mutual fund holders
(m)
REPLIGEN CORP Overview
View more →(m)
(m)
- SEC CIK
- 730272
- Industry (SIC)
- 2836 Biological Products, (No Diagnostic Substances)
- Country of operation
- United States
- Business address
- 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, Massachusetts, 02453, United States
- Fiscal year end
- 1231
- Phone
- 7814499560
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |